Arisha Patel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3542900/publications.pdf

Version: 2024-02-01

1684188 1588992 11 308 5 8 citations h-index g-index papers 11 11 11 254 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2021, 22, 1290-1300.	10.7	178
2	The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer Tâ€cell lymphoma, nasal type, in the United States. Cancer, 2017, 123, 3176-3185.	4.1	51
3	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase Ila Multiple Basket Study. Cancer Discovery, 2022, 12, 654-669.	9.4	34
4	MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors Journal of Clinical Oncology, 2021, 39, 3004-3004.	1.6	27
5	Machineâ€earning algorithms for predicting hospital reâ€admissions in sickle cell disease. British Journal of Haematology, 2021, 192, 158-170.	2.5	8
6	Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission. Oncology Research, 2021, 28, 811-814.	1.5	3
7	Machine Learning Algorithms in Predicting Hospital Readmissions in Sickle Cell Disease. Blood, 2019, 134, 982-982.	1.4	3
8	Pertuzumab Plus Trastuzumab for Treatment-Refractory <i>HER2</i> -Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm. JCO Clinical Cancer Informatics, 2022, , .	2.1	3
9	Abstract LB012: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort. , 2021, , .		1
10	Modified ketogenic diet in lymphoma: A case series in the Veteran Affairs Pittsburgh Healthcare System Journal of Clinical Oncology, 2018, 36, e24222-e24222.	1.6	0
11	Natural History of Human Epidermal Growth Factor Receptor 2–Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice. JCO Clinical Cancer Informatics, 2022, 6, e2100133.	2.1	0